CureVac (CVAC) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

CVAC Stock Forecast

CureVac stock forecast is as follows: an average price target of $29.00 (represents a 990.23% upside from CVAC’s last price of $2.66) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.

CVAC Price Target

The average price target for CureVac (CVAC) is $29.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $37.00 to $21.00. This represents a potential 990.23% upside from CVAC's last price of $2.66.

CVAC Analyst Ratings

Buy

According to 2 Wall Street analysts, CureVac's rating consensus is 'Buy'. The analyst rating breakdown for CVAC stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

CureVac Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Jan 07, 2023	Eun Yang	Jefferies	-	-	154.24%	689.47%
Apr 22, 2022		JMP Securities	-	-	120.37%	1290.98%

Row per page

Go to

The latest CureVac stock forecast, released on Jan 07, 2023 by Eun Yang from Jefferies, set a price target of $21.00, which represents a 154.24% increase from the stock price at the time of the forecast ($8.26), and a 689.47% increase from CVAC last price ($2.66).

CureVac Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	-
Avg Price Target	-	-	-
Last Closing Price	$2.66	$2.66	$2.66
Upside/Downside	-100.00%	-100.00%	-100.00%

In the current month, the average price target of CureVac stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to CureVac's last price of $2.66. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Jan 07, 2023	Jefferies		Buy	Upgrade
Nov 17, 2022	JMP Securities	Market Outperform	Market Outperform	Hold

Row per page

Go to

CureVac's last stock rating was published by Jefferies on Jan 07, 2023. The company Upgrade its CVAC rating from "null" to "Buy".

CureVac Financial Forecast

CureVac Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
Revenue	-	-	-	-	-	-	-	-	-	-	-	$7.13M	$11.69M	$11.21M	$20.15M	$24.37M	$41.23M	$29.34M	$22.39M	$10.03M	$6.04M	$5.16M
Avg Forecast	$22.97M	$21.26M	$19.68M	$24.78M	$8.57M	$3.34M	$8.02M	$10.62M	$38.91M	$17.02M	$20.62M	$9.70M	$17.48M	$20.40M	$17.86M	$22.99M	$4.16M	$23.47M	$12.34M	$12.34M	$3.68M	$53.06M
High Forecast	$42.00M	$38.87M	$35.97M	$45.30M	$16.51M	$6.11M	$14.66M	$19.42M	$71.14M	$17.47M	$37.70M	$17.74M	$31.96M	$20.40M	$17.86M	$22.99M	$4.16M	$23.47M	$12.34M	$12.34M	$3.68M	$53.06M
Low Forecast	$3.94M	$3.65M	$3.38M	$4.25M	$629.64K	$573.69K	$1.38M	$1.82M	$6.68M	$16.56M	$3.54M	$1.67M	$3.00M	$20.40M	$17.86M	$22.99M	$4.16M	$23.47M	$12.34M	$12.34M	$3.68M	$53.06M
# Analysts	1	1	1	1	2	1	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.73%	0.67%	0.55%	1.13%	1.06%	9.91%	1.25%	1.81%	0.81%	1.64%	0.10%

CureVac's average Quarter revenue forecast for Jun 23 based on 2 analysts is $20.62M, with a low forecast of $3.54M, and a high forecast of $37.70M. CVAC's average Quarter revenue forecast represents a 189.21% increase compared to the company's last Quarter revenue of $7.13M (Mar 23).

CureVac EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	1	2	1	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2
EBITDA	-	-	-	-	-	-	-	-	-	-	-	$-50.92M	$-126.38M	$-40.41M	$-49.40M	$-4.17M	$96.00K	$-141.56M	$-144.08M	$-105.66M	$-46.25M	$-32.88M
Avg Forecast	$-22.97M	$-21.26M	$-19.68M	$-24.78M	$-8.57M	$-3.34M	$-8.02M	$-10.62M	$-38.91M	$-17.02M	$-20.62M	$-9.70M	$-17.48M	$-20.40M	$-17.86M	$-6.24M	$-4.16M	$-23.47M	$-12.34M	$-12.34M	$-3.68M	$-36.80M
High Forecast	$-3.94M	$-3.65M	$-3.38M	$-4.25M	$-629.64K	$-573.69K	$-1.38M	$-1.82M	$-6.68M	$-16.56M	$-3.54M	$-1.67M	$-3.00M	$-20.40M	$-17.86M	$-4.99M	$-4.16M	$-23.47M	$-12.34M	$-12.34M	$-3.68M	$-29.44M
Low Forecast	$-42.00M	$-38.87M	$-35.97M	$-45.30M	$-16.51M	$-6.11M	$-14.66M	$-19.42M	$-71.14M	$-17.47M	$-37.70M	$-17.74M	$-31.96M	$-20.40M	$-17.86M	$-7.49M	$-4.16M	$-23.47M	$-12.34M	$-12.34M	$-3.68M	$-44.16M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	5.25%	7.23%	1.98%	2.77%	0.67%	-0.02%	6.03%	11.67%	8.56%	12.57%	0.89%

1 analysts predict CVAC's average Quarter EBITDA for Mar 22 to be $-6.24M, with a high of $-4.99M and a low of $-7.49M. This is -6597.48% lower than CureVac's previous annual EBITDA (Dec 21) of $96.00K.

CureVac Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	1	2	1	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2
Net Income	-	-	-	-	-	-	-	-	-	-	-	$-57.42M	$-128.78M	$-47.57M	$-57.58M	$-15.09M	$-1.94M	$-144.02M	$-152.06M	$-113.70M	$-58.15M	$-36.83M
Avg Forecast	$-22.81M	$-25.38M	$-29.56M	$-34.80M	$-52.88M	$315.27M	$-62.84M	$-60.43M	$-44.75M	$-50.62M	$-53.80M	$-73.91M	$-67.69M	$-60.02M	$-57.67M	$-22.58M	$-146.16M	$-158.83M	$-190.56M	$-127.71M	$-115.38M	$-41.22M
High Forecast	$1.75M	$1.95M	$2.27M	$2.67M	$11.27M	$315.67M	$4.82M	$4.64M	$3.44M	$3.89M	$4.13M	$5.67M	$5.20M	$-60.02M	$-57.67M	$-18.06M	$-146.16M	$-158.83M	$-190.56M	$-127.71M	$-115.38M	$-32.97M
Low Forecast	$-47.38M	$-52.72M	$-61.40M	$-72.27M	$-116.16M	$314.87M	$-130.51M	$-125.51M	$-92.93M	$-105.12M	$-111.73M	$-153.49M	$-140.58M	$-60.02M	$-57.67M	$-27.09M	$-146.16M	$-158.83M	$-190.56M	$-127.71M	$-115.38M	$-49.46M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.78%	1.90%	0.79%	1.00%	0.67%	0.01%	0.91%	0.80%	0.89%	0.50%	0.89%

CureVac's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CVAC's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

CureVac SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	1	2	1	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2
SG&A	-	-	-	-	-	-	-	-	-	-	-	$19.70M	$23.66M	$22.08M	$23.07M	$20.60M	$14.61M	$22.66M	$31.78M	$19.90M	$11.81M	$9.22M
Avg Forecast	$32.48M	$30.06M	$27.82M	$35.03M	$12.12M	$4.72M	$11.34M	$15.02M	$55.02M	$24.06M	$29.15M	$13.72M	$24.72M	$29.26M	$25.62M	$32.97M	$5.97M	$33.66M	$17.70M	$17.69M	$5.28M	$10.32M
High Forecast	$59.39M	$54.96M	$50.87M	$64.05M	$23.34M	$8.64M	$20.73M	$27.46M	$100.60M	$24.71M	$53.30M	$25.08M	$45.19M	$29.26M	$25.62M	$32.97M	$5.97M	$33.66M	$17.70M	$17.69M	$5.28M	$12.38M
Low Forecast	$5.58M	$5.16M	$4.78M	$6.02M	$890.34K	$811.23K	$1.95M	$2.58M	$9.45M	$23.41M	$5.01M	$2.36M	$4.24M	$29.26M	$25.62M	$32.97M	$5.97M	$33.66M	$17.70M	$17.69M	$5.28M	$8.26M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	1.44%	0.96%	0.75%	0.90%	0.62%	2.45%	0.67%	1.80%	1.12%	2.24%	0.89%

CureVac's average Quarter SG&A projection for Jun 23 is $29.15M, based on 2 Wall Street analysts, with a range of $5.01M to $53.30M. The forecast indicates a 47.96% rise compared to CVAC last annual SG&A of $19.70M (Mar 23).

CureVac EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	1	2	1	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2
EPS	-	-	-	-	-	-	-	-	-	-	-	$-0.27	$-0.68	$-0.26	$-0.31	$-0.08	$-0.01	$-0.80	$-0.84	$-0.62	$-0.32	$-0.20
Avg Forecast	$-0.10	$-0.11	$-0.13	$-0.16	$-0.24	$1.41	$-0.28	$-0.27	$-0.20	$-0.23	$-0.24	$-0.33	$-0.30	$-0.27	$-0.26	$-0.57	$-0.65	$-0.71	$-0.85	$-0.57	$-0.51	$-0.35
High Forecast	$0.01	$0.01	$0.01	$0.01	$0.05	$1.41	$0.02	$0.02	$0.02	$0.02	$0.02	$0.03	$0.02	$-0.27	$-0.26	$-0.57	$-0.65	$-0.71	$-0.85	$-0.57	$-0.51	$-0.35
Low Forecast	$-0.21	$-0.24	$-0.27	$-0.32	$-0.52	$1.40	$-0.58	$-0.56	$-0.41	$-0.47	$-0.50	$-0.68	$-0.63	$-0.27	$-0.26	$-0.57	$-0.65	$-0.71	$-0.85	$-0.57	$-0.51	$-0.35
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.82%	2.25%	0.97%	1.21%	0.14%	0.02%	1.13%	0.99%	1.09%	0.62%	0.58%

According to undefined Wall Street analysts, CureVac's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CVAC previous annual EPS of $NaN (undefined).

CVAC Forecast FAQ

Is CureVac a good buy?

Yes, according to 2 Wall Street analysts, CureVac (CVAC) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of CVAC's total ratings.

What is CVAC's price target?

CureVac (CVAC) average price target is $29 with a range of $21 to $37, implying a 990.23% from its last price of $2.66. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will CureVac stock go up soon?

According to Wall Street analysts' prediction for CVAC stock, the company can go up by 990.23% (from the last price of $2.66 to the average price target of $29), up by 1290.98% based on the highest stock price target, and up by 689.47% based on the lowest stock price target.

Can CureVac stock reach $4?

CVAC's average twelve months analyst stock price target of $29 supports the claim that CureVac can reach $4 in the near future.

What are CureVac's analysts' financial forecasts?

CureVac's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $30.55M (high $56.69M, low $4.4M), average EBITDA is $-30.548M (high $-4.404M, low $-56.693M), average net income is $139.11M (high $336.4M, low $-57.307M), average SG&A $43.2M (high $80.17M, low $6.23M), and average EPS is $0.62 (high $1.5, low $-0.255). CVAC's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $88.68M (high $162.14M, low $15.23M), average EBITDA is $-88.684M (high $-15.228M, low $-162M), average net income is $-113M (high $8.64M, low $-234M), average SG&A $125.4M (high $229.27M, low $21.53M), and average EPS is $-0.502 (high $0.0385, low $-1.042).

Did the CVAC's actual financial results beat the analysts' financial forecasts?

Based on CureVac's last annual report (Dec 2022), the company's revenue was $67.42M, which missed the average analysts forecast of $78.73M by -14.37%. Apple's EBITDA was $-223M, beating the average prediction of $-61.982M by 259.94%. The company's net income was $-249M, beating the average estimation of $-208M by 19.75%. Apple's SG&A was $89.41M, missing the average forecast of $112.56M by -20.57%. Lastly, the company's EPS was $-1.32, missing the average prediction of $-1.396 by -5.46%. In terms of the last quarterly report (Mar 2023), CureVac's revenue was $7.13M, missing the average analysts' forecast of $9.7M by -26.51%. The company's EBITDA was $-50.922M, beating the average prediction of $-9.7M by 424.94%. CureVac's net income was $-57.419M, missing the average estimation of $-73.907M by -22.31%. The company's SG&A was $19.7M, beating the average forecast of $13.72M by 43.65%. Lastly, the company's EPS was $-0.27, missing the average prediction of $-0.329 by -18.05%